A Pooled Analysis of Fall Incidence From Placebo ‐controlled Trials of Denosumab
In conclusion, denosumab may reduce the risk of falls in addition to its established fracture risk reduction by reducing bone resorption and increasing bone mass. These observations require further exploration and confirmation in studies with muscle function or falls as the primary outcome.This article is protected by copyright. All rights reserved.
Source: Journal of Bone and Mineral Research - Category: Orthopaedics Authors: Pojchong Chotiyarnwong,
Eugene McCloskey,
Richard Eastell,
Michael R. McClung,
Evelien Gielen,
John Gostage,
Michele McDermott,
Arkadi Chines,
Shuang Huang,
Steven R. Cummings Tags: Original Article Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Orthopaedics | Osteoporosis | Prostate Cancer | Study | Women | Xgeva